The production of tuberculosis (TB) research and innovation in Latin America during the past decade has notably improved. Its role in the acceleration of the decline of the average annual TB incidence rate by 2.5% from 2017 to 2018 is still unclear, but it is looking promising that the region will meet the End TB Strategy targets set for 2030.

Well performed and high-quality research and evidence is critical for improving national TB control programme outcomes. In Latin America, this need is most apparent when responding to the multidrug-resistant TB epidemic.

There is an urgent need for technological breakthroughs to accelerate by an average of 17% per year if the decline in TB incidence rate is to meet the target set for 2030. Intensified research and innovation, identified as one of the three essential pillars of the End TB Strategy, has scarcely been achieved in the region due to political and economic context. This will be analysed further in this article.

在过去十年中，拉丁美洲的结核病 (TB) 研究和创新成果显着改善。它在 2017 年至 2018 年加速结核病年均发病率下降 2.5% 方面的作用尚不清楚，但该地区有望实现 2030 年终结结核病战略目标。

执行良好且高质量的研究和证据对于改善国家结核病控制计划的成果至关重要。在拉丁美洲，这种需求在应对耐多药结核病流行时最为明显。

如果要实现 2030 年结核病发病率下降的目标，迫切需要技术突破，平均每年加速 17%。加强研究和创新，被确定为“终结”的三大重要支柱之一由于政治和经济背景，结核病战略在该地区几乎没有实现。这将在本文中进一步分析。